Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00525135 · ClinicalTrials.gov registry record · Phase 2
Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer
A Phase 2 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00525135 is a Phase 2 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 5 participants.
The verdict
NCT00525135, a Phase 2 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
RATIONALE: Drugs such as valproic acid may make thyroid cancers more radioiodine sensitive, which will allow for detection of tumor and make further ablation treatment effective.
Interventions
- DRUG Valproic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00525135
The ClinicalTrials.gov registry entry for NCT00525135 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Valproic Acid is the first listed.
NCT00525135 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00525135 about?
NCT00525135 is a clinical study titled "Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer". RATIONALE: Drugs such as valproic acid may make thyroid cancers more radioiodine sensitive, which will allow for detection of tumor and make further ablation treatment effective.
What is the current status of trial NCT00525135?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2007-08. Estimated completion is 2009-03.
What interventions are being tested in trial NCT00525135?
The interventions under investigation include: Valproic Acid (DRUG).
Who is sponsoring clinical trial NCT00525135?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.